Budget and sustainability challenges faced by health care facilities as well as the rising acceptance of reprocessing among OEMs and physicians will support growth in the overall US market for reprocessed devices through 2026. Growth will be particularly strong in the reprocessed EP diagnostic catheter and reprocessed laparoscopic direct energy device segments, mainly driven by the high per-unit cost savings associated with reprocessed devices over their OEM counterparts.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for reprocessed devices in the US across a 10-year period.
The US reprocessed device market will grow moderately through 2026.
What factors are driving and limiting the market?
Which reprocessed device market will see the strongest growth in the US, and why?
Which reprocessed device segments will decline in size?
Numerous devices received FDA approval for reprocessing in 2017.
Which device segments have seen the most approvals? Why is this the case?
Which reprocessors are seeing the most action in terms of device approvals within this space?
The reprocessed device market is primarily hindered by pushback from physicians.
What factors have made physicians hesitant to use reprocessed devices?
How and why will physicians' attitudes change going forward?
What are other factors limiting the medical device reprocessing market?
- Reprocessed Devices - Market Insights - United States
Author(s): Lucy Sha Guan, MSc
Lucy Guan is a senior analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, with extensive knowledge in the markets for endoscope servicing, video and high-tech hardware devices, and laparoscopic devices. Lucy holds an Honors Bachelor's degree in Biochemistry and Health & Disease and a Master's degree in Medical Science from the University of Toronto.